Page last updated: 2024-12-10

sf 837

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

midecamycin: minor descriptor (75-80); on-line search LEUCOMYCINS (75-80); Index Medicus search ANTIBIOTICS (75-80); macrolide antibiotic [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5282169
CHEMBL ID444963
CHEBI ID31845
SCHEMBL ID141581
MeSH IDM0086939

Synonyms (71)

Synonym
espinomycin a
midecamycin a(sub 1)
7-(formylmethyl)-4,10-dihydroxy-5-methoxy-9,16-dimethyl-2-oxooxacyclohexadeca-11,13-dien-6-yl 3,6-dideoxy-4-o-(2,6-dideoxy-3-c-methyl-alpha-l-ribo-hexopyranosyl)-3-(dimethylamino)-beta-d-glucopyranoside 4',4''-dipropionate (ester)
midecamicina [inn-spanish]
midecamycin [inn:dcf:jan]
macropen
madecacine
turimycin p(sub 3)
7-(formylmethyl)-4,10-dihydroxy-5-methoxy-9,16-dimethyl-2-oxooxacyclohexadeca-11,13-dien-6-yl 3,6-dideoxy-4-o-(2,6-dideoxy-3-c-methyl-alpha-l-ribo-hexopyranosyl)-3-(dimethylamino)-beta-d-glucopyranoside 4',4'-dipropionate (ester)
antibiotic yl 704 b1
macro-dil
platenomycin b1
leucomycin v, 3,4(sup b)-dipropanoate
nsc 154011
leucomycin v, 3,4b-dipropanoate
midecamycine [inn-french]
midecamycinum [inn-latin]
einecs 252-578-0
antibiotic sf 837 a1
NCGC00016830-01
cas-35457-80-8
sf 837
antibiotic sf 837
turimycin p3
yl 704 b1
midecamycin
medemycin
nsc-154011
antibiotic sf-837
D01339
midecamycin (jp17/inn)
medemycin (tn)
sf-837
myoxam
normicina
midecamycin a1
CHEMBL444963
(4r,5s,6s,7r,9r,10r,11e,13e,16r)-6-(((2s,3r,4r,5s,6r)-4-(dimethylamino)-3-hydroxy-5-(((2s,4r,5s,6s)-4-hydroxy-4,6-dimethyl-5-(propionyloxy)tetrahydro-2h-pyran-2-yl)oxy)-6-methyltetrahydro-2h-pyran-2-yl)oxy)-10-hydroxy-5-methoxy-9,16-dimethyl-2-oxo-7-(2-ox
dtxsid5045463 ,
dtxcid3025463
tox21_110635
midecamycinum
midecamycine
midecamicina
n34z0y5uh7 ,
rubimycin
unii-n34z0y5uh7
momicine
medemycin a1
medecamycin a1
mydecamycin a1
S5560
AKOS022185298
SCHEMBL141581
midecamycin [who-dd]
midecamycin [inn]
midecamycin [jan]
midecamycin [mart.]
midecamycin a1 [mi]
CS-5909
HY-B1908
W-106669
midecamycin), antibiotic for culture media use only
CHEBI:31845
DB13456
midecamycin,(s)
Q2636110
CCG-270507
H10500
espinomycin a;medecamycin a1;platenomycin b1;rubimycin;turimycin p3
Z2583154301

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Based on these results, midecamycin acetate dry syrup can be evaluated to be a highly safe macrolide in clinical use."( A survey of the side effects of midecamycin acetate (Miocamycin) dry syrup after marketing.
Iida, M; Maruyama, K; Mayama, T; Nakazawa, T, 1990
)
0.28

Bioavailability

ExcerptReferenceRelevance
"The absorption and excretion of rokitamycin (RKM) in dry syrup form for children were studied following oral administration to fasted healthy volunteers with high gastric acidity as a suitable model to estimate bioavailability of RKM in children."( [Studies on absorption and excretion of rokitamycin dry syrup in healthy volunteers].
Endo, S; Ishioka, T; Morishita, M; Ohta, K; Sakai, A; Suzuki, T; Yasuda, N, 1988
)
0.27
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" From the above results, it was concluded that a daily dosage of 300 mg of RU was equal in usefulness to 600 mg daily of MOM in the treatment of mild to moderate pneumonia."( [Double-blind comparative study of roxithromycin (RU 28965) and midecamycin acetate (MOM) in the treatment of pneumonia].
Hino, J; Hiraga, Y; Kishimoto, T; Nakagawa, Y; Nakayama, I; Niki, Y; Saito, A; Soejima, R; Sumi, M; Tomizawa, M, 1989
)
0.28
" Since serum and tissue concentrations of Mb-12 after 200 mg administration in humans have been reported to be 1-2 micrograms/ml, it can be presumed that the causative bacteria would be eradicated by a usual dosage of MOM used in the present study."( [Midecamycin acetate-susceptibility of clinical isolates from dental and oral surgical infections].
Deguchi, K; Fukayama, S; Ikegami, R; Matsumoto, Y; Nishimura, Y; Oda, S; Sato, K; Tanaka, S; Yokota, N; Yoshihara, H, 1986
)
0.27
" The study was made by the double-blind controlled trial at the dosage of daily 600 mg in TMS group and 1,200 mg in MDM group."( [Clinical evaluation of the TMS-19-Q.GC tablet on superficial suppurative disease. A comparative double blind study with midecamycin].
Fujita, K; Kukita, A; Miura, Y; Nonami, E; Shigeno, Y; Shishiba, T; Tagami, H; Tanita, Y; Tsukinaga, I; Watanabe, S, 1985
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
organic molecular entityAny molecular entity that contains carbon.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TDP1 proteinHomo sapiens (human)Potency11.67710.000811.382244.6684AID686978; AID686979
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (104)

TimeframeStudies, This Drug (%)All Drugs %
pre-199045 (43.27)18.7374
1990's36 (34.62)18.2507
2000's14 (13.46)29.6817
2010's4 (3.85)24.3611
2020's5 (4.81)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.47

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.47 (24.57)
Research Supply Index4.86 (2.92)
Research Growth Index4.33 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.47)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials14 (12.28%)5.53%
Reviews1 (0.88%)6.00%
Case Studies10 (8.77%)4.05%
Observational0 (0.00%)0.25%
Other89 (78.07%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]